Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RNS 60

Next Previous
Drug Profile

RNS 60

Alternative Names: Oxygenated saline; RNS-60

Latest Information Update: 29 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Queens University; Revalesio
  • Developer Revalesio; Rush University
  • Class Anti-ischaemics; Antiasthmatics; Antidementias; Antiparkinsonians; Neuroprotectants; Vascular disorder therapies
  • Mechanism of Action G protein-coupled receptor modulators; HSP90 heat-shock protein modulators; Ion channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Amyotrophic lateral sclerosis; Asthma; Ischaemic stroke; Multiple sclerosis
  • Preclinical Traumatic brain injuries
  • No development reported Alzheimer's disease; Parkinson's disease
  • Discontinued Myocardial infarction

Most Recent Events

  • 16 Apr 2026 Revalesio Corporation withdraws a phase II trial for Amyotrophic lateral sclerosis in USA (Inhalation), prior to enrolment (NCT02988297)
  • 05 Mar 2026 Updated efficacy data from a phase II RESCUE trial in Stroke released by Revalesio
  • 31 Jul 2025 RNS 60 receives Fast Track designation for Ischaemic stroke [Injection,Infusion] in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top